{"id":14986,"date":"2021-12-23T16:15:43","date_gmt":"2021-12-23T10:45:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=14986"},"modified":"2021-12-23T16:26:02","modified_gmt":"2021-12-23T10:56:02","slug":"follicular-lymphoma-highlights-ash-2021","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021","title":{"rendered":"Major Highlights of Follicular Lymphoma (FL) in ASH 2021"},"content":{"rendered":"\n<p><strong>ASH 2021<\/strong>,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveInsight, maintaining an essence of brevity, has compiled the conference\u2019s major highlights so that you do not miss out on these expansions in hematology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-follicular-lymphoma-highlights-ash-2021\">Follicular Lymphoma Highlights: ASH 2021<\/h2>\n\n\n\n<p>Major Pharma companies involved in presenting their FL data readouts during the conference included <strong>Roche<\/strong>,<strong> Novartis<\/strong>,<strong> BMS<\/strong>,<strong> Incyte<\/strong>,and <strong>Genmab.<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Innovent Biologics announced durable responses of parsaclisib in R\/R FL from a Phase II trial: <\/strong>Major Key player <strong>Innovent Biologics<\/strong> announced the results from its pivotal Phase II study for parsaclisib in patients with relapsed or refractory (R\/R) FL. As per the key results presented at ASH 2021, in the 24 evaluable patients with R\/R FL, the <strong>ORR was reported to be 91.7%<\/strong>,<strong> CR was 6.7 %<\/strong>, and<strong> PR was 75%.<\/strong> Parsaclisib was found to be well tolerated with a manageable safety profile. After analyzing the trial results, DelveInsight believes that parsaclisib is a promising drug and may provide valuable treatment for patients with R\/R FL.<\/li><li><strong>Fixed-duration treatment with mosunetuzumab inducing deep and durable responses in heavily pretreated patients with R\/R FL<\/strong>: <strong>Roche <\/strong>presented the trailblazing data from their pivotal Phase I\/II study in patients with R\/R FL who have received \u22652 prior lines of therapy. The company also mentioned that mosunetuzumab is the first T-cell\u2013engaging bispecific antibody to demonstrate clinically meaningful outcomes by meeting the primary endpoint for patients with R\/R FL in a pivotal Phase II setting. According to the results presented, DelveInsight believes that mosunetuzumab could potentially become a highly efficacious treatment option that can be administered without cell collection or genetic engineering.<\/li><li><strong>Roche<\/strong> also presented early phase data from its Ib study evaluating <strong>mosunetuzumab in combination with lenalidomide <\/strong>in patients with R\/R FL, which demonstrated encouraging preliminary efficacy and a tolerable safety profile.<\/li><li><strong>Novartis announced strong responses of Kymriah (tisagenlecleucel) in a Phase II ELARA study in patients with high-risk R\/R FL: <\/strong>According to the positive results presented at ASH 2021, Novartis mentioned that Kymriah induced high rates of durable responses in patients for the majority of high-risk disease subgroups, who typically have a poor prognosis. The company revealed that<strong> Kymriah<\/strong> was well tolerated as patients have been experiencing long-lasting responses with a low risk of severe adverse events, which will potentially lead to transformative results and a positive impact on the health system.<\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveInsight, maintaining an essence of brevity, has compiled [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":14987,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[18917,18918,18834,18919],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-14986","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-ash","tag-ash-2021","tag-follicular-lymphoma","tag-healthcare-conference","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Major Highlights of Follicular Lymphoma (FL) in ASH 2021 -<\/title>\n<meta name=\"description\" content=\"Major Pharma companies presenting their follicular lymphoma data readouts during conference included Roche, Novartis, BMS, Incyte. etc.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Major Highlights of Follicular Lymphoma (FL) in ASH 2021 -\" \/>\n<meta property=\"og:description\" content=\"Major Pharma companies presenting their follicular lymphoma data readouts during conference included Roche, Novartis, BMS, Incyte. etc.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-23T10:45:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-23T10:56:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/23161444\/Follicular-Lymphoma-Highlights.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Major Highlights of Follicular Lymphoma (FL) in ASH 2021 -","description":"Major Pharma companies presenting their follicular lymphoma data readouts during conference included Roche, Novartis, BMS, Incyte. etc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021","og_locale":"en_US","og_type":"article","og_title":"Major Highlights of Follicular Lymphoma (FL) in ASH 2021 -","og_description":"Major Pharma companies presenting their follicular lymphoma data readouts during conference included Roche, Novartis, BMS, Incyte. etc.","og_url":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-12-23T10:45:43+00:00","article_modified_time":"2021-12-23T10:56:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/23161444\/Follicular-Lymphoma-Highlights.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021","url":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021","name":"Major Highlights of Follicular Lymphoma (FL) in ASH 2021 -","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/23161444\/Follicular-Lymphoma-Highlights.png","datePublished":"2021-12-23T10:45:43+00:00","dateModified":"2021-12-23T10:56:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/90e3f864ebcfcaa34b1be0e9ae5909e1"},"description":"Major Pharma companies presenting their follicular lymphoma data readouts during conference included Roche, Novartis, BMS, Incyte. etc.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/follicular-lymphoma-highlights-ash-2021#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/23161444\/Follicular-Lymphoma-Highlights.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/23161444\/Follicular-Lymphoma-Highlights.png","width":772,"height":482,"caption":"Follicular Lymphoma Highlights"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/90e3f864ebcfcaa34b1be0e9ae5909e1","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7f5e159702916007828000ba2479aa162e568daf1ea6bf5b637e8ed4c71407ce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f5e159702916007828000ba2479aa162e568daf1ea6bf5b637e8ed4c71407ce?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/anigam"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/23161444\/Follicular-Lymphoma-Highlights-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">ASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">ASH 2021<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Healthcare Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ASH<\/span>","<span class=\"advgb-post-tax-term\">ASH 2021<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Dec 23, 2021","modified":"Updated on Dec 23, 2021"},"absolute_dates_time":{"created":"Posted on Dec 23, 2021 4:15 pm","modified":"Updated on Dec 23, 2021 4:26 pm"},"featured_img_caption":"Follicular Lymphoma Highlights","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/14986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=14986"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/14986\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/14987"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=14986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=14986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=14986"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=14986"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=14986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}